Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2008, p. 1533-1537, Vol. 52, No. 4
0066-4804/08/$08.00+0 doi:10.1128/AAC.01254-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype
Brian T. Tsuji,1,2*
Christof von Eiff,3
Pamela A. Kelchlin,1
Alan Forrest,1 and
Patrick F. Smith1,2,
Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences—Buffalo, and The New York State Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, State University of New York, Buffalo, New York 14260,1
Departments of Pharmacy and Medicine, Roswell Park Cancer Institute, Buffalo, New York 14260,2
Institute of Medical Microbiology, University of Münster, Münster, Germany3
Received 25 September 2007/
Returned for modification 30 October 2007/
Accepted 23 January 2008
The in vitro bactericidal activities of vancomycin against Staphylococcus aureus hemB mutants displaying the small-colony-variant phenotype and their parental strains were evaluated. Vancomycin killing activities against hemB mutants were markedly attenuated, demonstrating approximately 50% less effect, a result which was well described by a Hill-type pharmacodynamic model.
* Corresponding author. Mailing address: School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, 331 Cooke Hall, Buffalo, NY 14260. Phone: (716) 881-7543. Fax: (716) 645-2886. E-mail:
btsuji{at}buffalo.edu
Published ahead of print on 19 February 2008.
Present address: Roche Pharmaceuticals, Nutley, NJ.
Antimicrobial Agents and Chemotherapy, April 2008, p. 1533-1537, Vol. 52, No. 4
0066-4804/08/$08.00+0 doi:10.1128/AAC.01254-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., Grayson, M. L.
(2010). Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications. Clin. Microbiol. Rev.
23: 99-139
[Abstract]
[Full Text]
-
Wu, M., von Eiff, C., Al Laham, N., Tsuji, B. T.
(2009). Vancomycin and Daptomycin Pharmacodynamics Differ against a Site-Directed Staphylococcus epidermidis Mutant Displaying the Small-Colony-Variant Phenotype. Antimicrob. Agents Chemother.
53: 3992-3995
[Abstract]
[Full Text]
-
Harigaya, Y., Bulitta, J. B., Forrest, A., Sakoulas, G., Lesse, A. J., Mylotte, J. M., Tsuji, B. T.
(2009). Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia. Antimicrob. Agents Chemother.
53: 3894-3901
[Abstract]
[Full Text]
-
Begic, D., von Eiff, C., Tsuji, B. T.
(2009). Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. J Antimicrob Chemother
63: 977-981
[Abstract]
[Full Text]
-
Bulitta, J. B., Ly, N. S., Yang, J. C., Forrest, A., Jusko, W. J., Tsuji, B. T.
(2009). Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
53: 46-56
[Abstract]
[Full Text]